Aligos chops off a hepatitis B program — again — after a patient was briefly hospitalized
Aligos is facing another setback after a Phase I study missed the mark and revealed safety issues for an antisense chronic hepatitis B program. And it’s spurring a broader internal shift.
The biotech announced Tuesday it will discontinue development of ALG-020572 after a chronic hepatitis B patient was sent to the hospital to treat an adverse event. Aligos said the subject experienced a “significant increase in alanine aminotransferase” after multiple doses and was one of four patients to see potentially drug-related ALT flares in this cohort.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.